文献速递头颈部肿瘤放疗姑息放疗与转移瘤

度伐利尤单抗联合西妥昔单抗与放疗治疗局部晚期头颈鳞癌的I/II期研究(DUCRO)

Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO).
PubMed 文献 · Clin Transl Radiat Oncol · 2018-02-07

DUCRO是一项开放标签、多中心、单臂I/II期研究,评估度伐利尤单抗联合西妥昔单抗和放疗在局部晚期头颈鳞癌中的疗效与安全性。主要终点为2年无进展生存期,计划入组高危喉、下咽及HPV阴性或阳性口咽癌患者,并在前12、24、36例患者后设安全性导入期。

要点

  • 度伐利尤单抗固定剂量1500 mg每4周一次,从放疗联合西妥昔单抗第1周开始,辅助治疗最长至放疗联合西妥昔单抗结束后6个月。
  • 放疗剂量为69.9 Gy/2.12 Gy,共33次;西妥昔单抗为放疗前1周400 mg/m2,之后每周250 mg/m2。
  • 入组高危喉、下咽、HPV阴性口咽或HPV阳性口咽(≥T2、≥N2b、≥10包/年)患者。

核心结论

  • DUCRO研究旨在验证PD-1/PD-L1检查点抑制与西妥昔单抗及放疗联合是否安全且具有抗肿瘤活性。

研究设计与样本

  • 开放标签、多中心、单臂I/II期研究,计划在前12、24、36例患者入组后开展安全性导入。

关键数值与推荐

  • 主要终点为2年无进展生存期(PFS)。
  • 放疗方案为69.9 Gy/2.12 Gy,共33次。
  • 西妥昔单抗为放疗前1周400 mg/m2,随后每周250 mg/m2。
  • 度伐利尤单抗固定剂量1500 mg每4周一次,从放疗联合西妥昔单抗第1周开始,辅助治疗最长至放疗联合西妥昔单抗结束后6个月。
  • 入组标准包括高危喉、下咽、HPV阴性口咽或HPV阳性口咽(≥T2、≥N2b、≥10包/年)患者。

临床怎么用

  • 该研究为局部晚期头颈鳞癌患者提供了一种将免疫检查点抑制剂整合入常规生物放疗的探索性治疗方案。

局限性

  • 原文未报告研究结果,无法评估疗效与安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION AND BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) has been increasingly recognized as an immune suppressive malignancy. The efficacy of immune checkpoint inhibitors (ICI's) in the context of recurrent/metastatic (R/M) setting anticipates the possible integration of immunotherapy into the therapeutic armamentarium of locally advanced disease. Durvalumab (DUR) is a humanized monoclonal IgG1, anti-PD-L1 antibody with promising data in R/M HNSCC. The aim of our study is to test the antitumor activity of a combined regimen incorporating an immune checkpoint inhibitor into a conventional bio-radiation strategy for the cure of unfavorable locally advanced HNSCC. METHODS/DESIGN: In this open label, multi-center, single-arm, phase I/II study, enrolled patients will receive Radiotherapy (RT) (69.9 Gy/2.12 Gy in 33 fractions) with concurrent Cetuximab (CTX) (400 mg/m2 1 week before RT start followed by 250 mg/m2 weekly) and DUR (fixed dose of 1500 mg every 4 weeks starting from RT-CTX week 1) followed by adjuvant DUR (to a maximum of 6 months after completion of RT-CTX). Primary endpoint of the study is 2-year progression-free survival (PFS). A safety run-in is planned after the enrollment of first 12, 24 and 36 patients. Patients affected by high-risk (≥N2a or ≥T3, any N) larynx, hypopharynx and HPV negative oropharynx or HPV-positive oropharynx (≥T2, ≥N2b, ≥10 pack/years) will be eligible. DISCUSSION: Conventional intensification strategies failed to provide any benefit for the cure of locally advanced HNSCC. For the still prevalent HPV-negative population and the high risk-HPV positive disease, there is an unmet need for alternative treatment paradigms. Potentially, the inhibition of the PD-1/PD-L1 checkpoint may synergize with both CTX and RT through immunologic interplay, ultimately aiming to reverse the HNSCC-induced immune suppression. The DUCRO study will seek to demonstrate if such a strategy may be safe and active. TRIAL REGISTRATION: NCT number: NCT03051906Eudract number: 2016-004668-20.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Bonomo P, Desideri I, Loi M, et al. Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO). Clin Transl Radiat Oncol. 2018. PMID: 29594250. doi:10.1016/j.ctro.2018.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。